NDA 022057 · Ferring
Endometrin
Progesterone · Vaginal · Progesterone
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Jun 21, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
897
206 Phase 3, 84 recruiting
FAERS reports
20,274
11,005 serious, 452 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 29, 2026.
ENDOMETRIN ® is indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks. ENDOMETRIN is a progesterone indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks.
Mechanism: Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ENDOMETRIN · PROGESTERONE 100MG · INSERT, VAGINAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Progesterone" as an intervention, any sponsor and status, largest first.
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433589 · 6,600 participants (planned) · Start Feb 2007 · Primary completion Mar 2020
Drug: anthracycline-based; docetaxel and capecitabine and 2 more · For: Breast Cancer
Sites: Amsterdam, Netherlands
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT01547741 · 4,242 participants · Start Apr 2012 · Primary completion May 31, 2022
Drug: Doxorubicin; Cyclophosphamide and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Phoenix, Arizona; Scottsdale, Arizona · 915 sites in all
- Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By SurgeryPivotal-lookingStatus unknown
Gruppo Italiano Mammella (GIM)Academic, hospital or other
NCT00541086 · 3,697 participants · Start Mar 2007 · Primary completion Jul 2020
Drug: anastrozole; exemestane and 2 more · For: Breast Cancer
Sites: Naples, Italy; Reggio Emilia, Italy; Rome, Italy · 5 sites in all
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast CancerPivotal-lookingCompleted
Canadian Cancer Trials GroupResearch network
NCT01101438 · 3,649 participants · Start Aug 13, 2010 · Primary completion Sep 21, 2021
Drug: metformin hydrochloride · For: Breast Cancer
Sites: Anchorage, Alaska; Fairbanks, Alaska; Scottsdale, Arizona · 344 sites in all
- Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00556374 · 3,420 participants · Start Dec 18, 2006 · Primary completion Oct 7, 2014
Drug: Placebo; Denosumab and 2 more · For: Breast Cancer
Sites: Baden, Austria; Braunau am Inn, Austria; Dornbirn, Austria · 46 sites in all
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast CancerPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT00070564 · 3,294 participants · Start Nov 2003 · Primary completion Jan 2015
Drug: pegfilgrastim; AC regimen and 3 more · For: Breast Cancer
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 542 sites in all
- Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer PatientsPivotal-lookingStatus unknown
Fengxi SuAcademic, hospital or other
NCT02132000 · 3,036 participants (planned) · Start Apr 2014 · Primary completion May 2020
Drug: toremifene or tamoxifen · For: Breast Cancer Patients in Premenopausal; Estrogen and/or Progesterone Receptor Positive
Sites: Guangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache1,856
- off label use1,663
- drug ineffective1,652
- fatigue1,574
- nausea1,315
- pain1,294
- exposure during pregnancy903
- foetal exposure during pregnancy903
- rash901
- dizziness820
- maternal exposure during pregnancy793
- hypersensitivity780
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 136 |
| 2005 | 154 |
| 2006 | 140 |
| 2007 | 114 |
| 2008 | 169 |
| 2009 | 235 |
| 2010 | 271 |
| 2011 | 243 |
| 2012 | 388 |
| 2013 | 366 |
| 2014 | 461 |
| 2015 | 822 |
| 2016 | 1,211 |
| 2017 | 984 |
| 2018 | 1,063 |
| 2019 | 1,243 |
| 2020 | 1,286 |
| 2021 | 1,265 |
| 2022 | 1,446 |
| 2023 | 1,603 |
| 2024 | 1,999 |
| 2025 | 2,194 |
| 2026 | 2,481 |
Recalls
1 FDA enforcement reports for this application.
Sep 19, 2013 · Class III · Terminated
Discoloration; due to prolonged heat exposure.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Endometrin (Progesterone, Micronized)
2024 spending
$9K
Beneficiaries
n/a
19 claims
Per beneficiary
n/a
$13.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,252 |
| 2021 | $21,299 |
| 2022 | $12,878 |
| 2023 | $8,161 |
| 2024 | $9,215 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of Micronized Progesterone for Sleep: A Systematic Review and Meta-analysis of Randomized Controlled Trial Data.
Nolan BJ, Liang B, Cheung AS · J Clin Endocrinol Metab 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Progestogens for preventing miscarriage: a network meta-analysis.
Devall AJ, Papadopoulou A, Podesek M, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.
· Lancet 2021 · Meta-Analysis, Systematic Review
- Progestogens in women with threatened miscarriage or recurrent miscarriage: A meta-analysis.
Zhao Y, D'Souza R, Gao Y, et al. · Acta Obstet Gynecol Scand 2024 · Meta-Analysis, Systematic Review
- A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy.
Coomarasamy A, Devall AJ, Cheed V, et al. · N Engl J Med 2019 · Comparative Study, Multicenter Study
- Estrogen for schizophrenia.
Chua WL, de Izquierdo SA, Kulkarni J, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
Sponsor: Ferring
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.